AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
SPARC to receive 55% equity in Tiller Therapeutics
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Subscribe To Our Newsletter & Stay Updated